University of Michigan
This study will identify the potential benefits of regulating platelet activation with sotagliflozin compared to other FDA-approved drugs known to limit platelet activation.
Inclusion Criteria: \- Exclusion Criteria: * Students under the direct supervision of Dr. Michael Holinstat * Subjects diagnosed with Type I diabetes or those with ketoacidosis * Subjects with a history of alcohol abuse, pancreatitis or pancreatic surgery, or subjects taking a ketogenic diet * Women who self-identify as being pregnant or who are planning to become pregnant during the 14 week study will be excluded from the study, as are those who are breastfeeding (women enrolled in the study will be given a urine pregnancy test at the start of each drug administration period to confirm pre…
400 mg/day SOTA Each drug will be given daily for 2 weeks.
81 mg/day Aspirin Each drug will be given daily for 2 weeks.
75 mg/day clopidogrel Each drug will be given daily for 2 weeks.
5 mg orally twice daily Eliquis Each drug will be given daily for 2 weeks.
Arctuva estimate
Verify or correct the compensation shown for this listing.